J Nucl Med. 2009; 50 (Supplement 2):1094
Oncological imaging with Ga-68 PET: The story so far
Zarni Win1 and
1 Hammersmith Hospital, Imperial College Healthcare Trust, Nuclear Medicine, London, United Kingdom
Learning Objectives: Ga-68 PET imaging is showing slow but steady progress when compared to F-18 FDG-PET. Advantage of in-house preparation of Ga-68 without necessity of cyclotron; new generator configuration with future possibility of freeze-dried kits would make it a promising future PET agent. This is a review to highlight the clinical utility of Ga-68 PET in oncology to date.
Summary: A thorough literature search was undertaken via internet. Our own experiences have been compared to international data.Recent resurgence in development of peptides labelled with radio-metals, for diagnostic/therapeutic purposes, resulted in new oncological Ga-68 PET imaging. Pre-clinical experience with animal models provides data regarding identification of Somatostatin receptors sub-types on many tumours and investigation of tracer kinetics/tumour uptake measurements using dynamic Ga68 PET. Ga-68 PET with Ga-68-DOTATOC and Ga-68-DOTANOC is employed in management of neuroendocrine tumors with diagnostic/therapeutic implications; phaeochromocytomas where it compliments present radiologic/scintigraphic procedures. Diagnosis/radiotherapy treatment planning for meningiomas is another potential use of Ga-68 PET. Limited studies have shown its utility in prostate and lung cancers but further studies are contemplated.Experience to date including our own shows improved clinical utility of Ga-68 PET imaging in oncology with prospects of additional indications in future.